1.40
price down icon3.45%   -0.05
pre-market  Vorhandelsmarkt:  1.40  
loading
Schlusskurs vom Vortag:
$1.45
Offen:
$1.41
24-Stunden-Volumen:
142.98K
Relative Volume:
0.53
Marktkapitalisierung:
$20.90M
Einnahmen:
$1.89M
Nettoeinkommen (Verlust:
$-17.92M
KGV:
-0.2093
EPS:
-6.69
Netto-Cashflow:
$-15.62M
1W Leistung:
-11.39%
1M Leistung:
+5.26%
6M Leistung:
-24.32%
1J Leistung:
-31.03%
1-Tages-Spanne:
Value
$1.30
$1.43
1-Wochen-Bereich:
Value
$1.30
$1.621
52-Wochen-Spanne:
Value
$0.7707
$6.40

Longeveron Inc Stock (LGVN) Company Profile

Name
Firmenname
Longeveron Inc
Name
Telefon
305-302-7158
Name
Adresse
1951 NW 7TH AVENUE, MIAMI
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
LGVN's Discussions on Twitter

Vergleichen Sie LGVN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LGVN
Longeveron Inc
1.40 20.90M 1.89M -17.92M -15.62M -6.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Longeveron Inc Stock (LGVN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-06 Eingeleitet ROTH MKM Buy

Longeveron Inc Aktie (LGVN) Neueste Nachrichten

pulisher
Mar 28, 2025

Longeveron Files $70 Million Mixed Shelf - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Longeveron Inc Files For Mixed Shelf Of Up To $70 MillionSEC Filing - MarketScreener

Mar 28, 2025
pulisher
Mar 23, 2025

Longeveron (NASDAQ:LGVN) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Pharma company behind Alzheimer’s treatment closer to FDA approval - The Business Journals

Mar 21, 2025
pulisher
Mar 20, 2025

FDA aligns with Longeveron on Alzheimer’s therapy trial By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

FDA aligns with Longeveron on Alzheimer’s therapy trial - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Longeveron announces outcome of Type B meeting with FDA on Lomecel-B - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease - The Manila Times

Mar 20, 2025
pulisher
Mar 20, 2025

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

FDA Clears BLA Pathway for Longeveron's Alzheimer's Cell Therapy | LGVN Stock News - Stock Titan

Mar 20, 2025
pulisher
Mar 11, 2025

Laromestrocel shows promise in Alzheimer’s trial By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron® Announces Nature Medicine Publication Of Results Of Phase 2A Clinical Trial Evaluating Laromestrocel (Lomecel-B(TM)) In Alzheimer'S Disease - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Laromestrocel shows promise in Alzheimer’s trial - Investing.com India

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease - The Manila Times

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron announces publication of results of Phase 2a trial of Lomecel-B - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron Inc. Reports Positive Phase 2a Results for Laromestrocel (Lomecel-B™) in Mild Alzheimer’s Disease Treatment - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Game-Changing Alzheimer's Treatment: Longeveron's Drug Delivers Cognitive Improvements in Nature Study - StockTitan

Mar 11, 2025
pulisher
Mar 07, 2025

Q1 Earnings Estimate for Longeveron Issued By Roth Capital - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Q1 Earnings Forecast for Longeveron Issued By HC Wainwright - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Q1 Earnings Forecast for Longeveron Issued By Roth Capital - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

FY2025 EPS Estimates for Longeveron Reduced by Analyst - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Call Transcript - MSN

Mar 06, 2025
pulisher
Mar 05, 2025

Longeveron® to Present at the 37th Annual Roth Conference - The Manila Times

Mar 05, 2025
pulisher
Mar 05, 2025

How Longeveron's Upcoming Roth Conference Appearance Could Spotlight Its Cellular Therapy Pipeline - StockTitan

Mar 05, 2025
pulisher
Mar 04, 2025

Longeveron Inc. Reports Strong 2024 Financial Growth - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Longeveron (NASDAQ:LGVN) Receives Buy Rating from HC Wainwright - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Longeveron Inc. Earnings Call: Growth and Challenges - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Longeveron Inc (NASDAQ: LGVN) Declines -0.65%: This $22.55 million Stock Could Go Down -557.89% - Stocks Register

Mar 03, 2025
pulisher
Mar 03, 2025

LGVN To Complete ELPIS II Enrollment By Q2, Time To Keep An Eye On NXGL, What's The Buzz At ACON? - RTTNews

Mar 03, 2025
pulisher
Mar 02, 2025

Earnings call transcript: Longeveron Q4 2024 sees revenue surge, stock gains - Investing.com Canada

Mar 02, 2025
pulisher
Mar 02, 2025

Longeveron Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Mar 02, 2025
pulisher
Feb 28, 2025

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Feb 28, 2025
pulisher
Feb 28, 2025

Can Longeveron's 237% Revenue Surge and Advanced Clinical Trial Transform Pediatric Heart Treatment? - StockTitan

Feb 28, 2025
pulisher
Feb 26, 2025

LONGEVERON Earnings Preview: Recent $LGVN Insider Trading, Hedge Fund Activity, and More - Nasdaq

Feb 26, 2025
pulisher
Feb 23, 2025

Longeveron (LGVN) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Feb 23, 2025
pulisher
Feb 21, 2025

Longeveron® Announces World Health Organization Approval of “laro - The National Law Review

Feb 21, 2025
pulisher
Feb 21, 2025

LGVNRLongeveron Latest Stock News & Market Updates - StockTitan

Feb 21, 2025
pulisher
Feb 21, 2025

Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025 - The Manila Times

Feb 21, 2025
pulisher
Feb 21, 2025

Longeveron Inc. to Announce Full-Year 2024 Financial Results and Company Update on February 28, 2025 - Nasdaq

Feb 21, 2025
pulisher
Feb 18, 2025

Longeveron Cellular Therapy Granted International Non-Proprietary Name -February 18, 2025 at 10:33 am EST - Marketscreener.com

Feb 18, 2025
pulisher
Feb 18, 2025

Longeveron’s Lomecel receives WHO non-proprietary name approval as laromestroce - TipRanks

Feb 18, 2025
pulisher
Feb 18, 2025

Longeveron® Announces World Health Organization Approval of - GlobeNewswire

Feb 18, 2025
pulisher
Feb 18, 2025

Breakthrough Alzheimer's Treatment Gets Official WHO RecognitionMajor Milestone for Rare Disease Therapy - StockTitan

Feb 18, 2025
pulisher
Feb 14, 2025

Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025 - Marketscreener.com

Feb 14, 2025
pulisher
Feb 14, 2025

Biotech Breakthrough: Longeveron Reveals Latest Regenerative Medicine Advances at Major Conference - StockTitan

Feb 14, 2025
pulisher
Feb 05, 2025

Longeveron announces board member resignation - MSN

Feb 05, 2025
pulisher
Jan 31, 2025

Longeveron announces board member resignation By Investing.com - Investing.com South Africa

Jan 31, 2025
pulisher
Jan 30, 2025

Longeveron Board Member Neil Hare Resigns - TipRanks

Jan 30, 2025

Finanzdaten der Longeveron Inc-Aktie (LGVN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):